Dapagliflozin/metformin/sitagliptin - George Medicines
Alternative Names: Dapagliflozin/sitagliptin/metformin - George Medicines; GMRx4; Metformin/sitagliptin/Dapagliflozin - George Medicines; Sitagliptin/dapagliflozin/metformin - George MedicinesLatest Information Update: 03 Aug 2022
At a glance
- Originator George Medicines
- Class Antihyperglycaemics; Benzhydryl compounds; Biguanides; Chlorobenzenes; Fluorobenzenes; Glucosides; Heart failure therapies; Ketones; Obesity therapies; Pyrans; Pyrazines; Small molecules; Triazoles; Urologics
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2022 George Medicines plans to launch dapagliflozin/metformin/sitagliptin in 2027 (George Medicines pipeline, July 2022)
- 22 Jul 2022 Efficacy data from a phase I trial in Type 2 diabetes mellitus released by George Medicines
- 20 Jul 2022 Phase-II clinical trials in Type 2 diabetes mellitus in Australia (PO) (George Medicines pipeline, July 2022)